Instrument Inactif

Autres langues Lexicon Pharmaceuticals, Inc. Nasdaq

Actions

US5288721047

Recherche biotechnologique et médicale

Autres langues

01/09	Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
31/08	Lexicon Pharmaceuticals Announces Results from Post Hoc Soloist-Whf Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
31/08	Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
24/08	Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
24/08	Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851
24/08	Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
07/08	Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
07/08	Lexicon Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss
06/08	Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M
06/08	Lexicon: Q2 Earnings Snapshot
06/08	Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
30/07	Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
27/07	Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy
27/07	Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment
27/07	Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Index
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Index
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Dynamic Index
29/06	Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Microcap Growth Benchmark Index